185 related articles for article (PubMed ID: 23773454)
21. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
22. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan DS; Nagashima T; Hoshino T; Waldman F; Pawlak K; Sadee W
Biochem J; 1990 Jun; 268(3):725-31. PubMed ID: 2114100
[TBL] [Abstract][Full Text] [Related]
24. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
25. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
Gore L; Stelljes M; Quinones R
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S35-9. PubMed ID: 18086346
[TBL] [Abstract][Full Text] [Related]
26. Older and new purine nucleoside analogs for patients with acute leukemias.
Robak P; Robak T
Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
[TBL] [Abstract][Full Text] [Related]
27. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
28. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
29. Activation of guanine-β-D-arabinofuranoside and deoxyguanosine to triphosphates by a common pathway blocks T lymphoblasts at different checkpoints.
Leanza L; Miazzi C; Ferraro P; Reichard P; Bianchi V
Exp Cell Res; 2010 Dec; 316(20):3443-53. PubMed ID: 20603113
[TBL] [Abstract][Full Text] [Related]
30. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
31. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
32. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
33. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
34. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
35. Forodesine in the treatment of cutaneous T-cell lymphoma.
Lewis DJ; Duvic M
Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I.
Kamath VP; Xue J; Juarez-Brambila JJ; Morris CB; Ganorkar R; Morris PE
Bioorg Med Chem Lett; 2009 May; 19(10):2624-6. PubMed ID: 19386498
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies.
Ogura M; Tsukasaki K; Nagai H; Uchida T; Oyama T; Suzuki T; Taguchi J; Maruyama D; Hotta T; Tobinai K
Cancer Sci; 2012 Jul; 103(7):1290-5. PubMed ID: 22448814
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
Kamath VP; Xue J; Juarez-Brambila JJ
Bioorg Med Chem Lett; 2009 May; 19(10):2627-9. PubMed ID: 19386496
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
Maruyama D; Tsukasaki K; Uchida T; Maeda Y; Shibayama H; Nagai H; Kurosawa M; Suehiro Y; Hatake K; Ando K; Yoshida I; Hidaka M; Murayama T; Okitsu Y; Tsukamoto N; Taniwaki M; Suzumiya J; Tamura K; Yamauchi T; Ueda R; Tobinai K
Ann Hematol; 2019 Jan; 98(1):131-142. PubMed ID: 29974231
[TBL] [Abstract][Full Text] [Related]
40. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
